Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
118.48
+2.15+1.85%
News
Up 1.8% — Tracking Baker Brothers' Portfolio: Q2 2026 Update (SeekingAlpha).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -3.25 | Insider Own | 23.61% | Shs Outstand | 82.26M | Perf Week | 1.26% |
| Market Cap | 9.75B | Forward P/E | - | EPS next Y | -4.99 | Insider Trans | -20.12% | Shs Float | 72.95M | Perf Month | -2.39% |
| Enterprise Value | 9.12B | PEG | - | EPS next Q | -1.25 | Inst Own | - | Short Float | 14.22% | Perf Quarter | 31.79% |
| Income | -299.00M | P/S | 92.82 | EPS this Y | -17.68% | Inst Trans | - | Short Ratio | 12.07 | Perf Half Y | 49.71% |
| Sales | 105.00M | P/B | 6.46 | EPS next Y | -30.50% | ROA | -18.21% | Short Interest | 10.37M | Perf YTD | 52.27% |
| Book/sh | 18.34 | P/C | 14.10 | EPS next 5Y | - | ROE | -21.50% | 52W High | 130.05 -8.90% | Perf Year | 142.89% |
| Cash/sh | 8.40 | P/FCF | - | EPS past 3/5Y | - | ROIC | -22.14% | 52W Low | 47.86 147.56% | Perf 3Y | 523.91% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -6.03% 2.78% | Gross Margin | - | Volatility | 3.87% 4.16% | Perf 5Y | 84.63% |
| Dividend TTM | - | EV/Sales | 86.86 | EPS Y/Y TTM | -9.06% | Oper. Margin | -333.54% | ATR (14) | 5.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.91 | Sales Y/Y TTM | 123.40% | Profit Margin | -285.41% | RSI (14) | 54.68 | Recom | 2.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.83 | EPS Q/Q | 34.74% | SMA20 | -0.04% | Beta | 1.94 | Target Price | 136.75 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | 490.91% | SMA50 | 3.55% | Rel Volume | 0.67 | Prev Close | 116.33 |
| Employees | 273 | LT Debt/Eq | 0.04 | Earnings | Nov 03 | SMA200 | 30.08% | Avg Volume | 851.56K | Price | 118.48 |
| IPO Date | Aug 21, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.99% 98.32% | Net Debt/EBITDA | 0.14 | Volume | 570,486 | Change | 1.85% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-10-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $65 → $180 |
| Aug-31-26 | Reiterated | Guggenheim | Buy | $135 → $170 |
| Aug-06-26 | Reiterated | Morgan Stanley | Overweight | $119 → $135 |
| Aug-06-26 | Reiterated | Barclays | Overweight | $133 → $139 |
| Aug-05-26 | Reiterated | Oppenheimer | Outperform | $120 → $125 |
| Jul-30-26 | Reiterated | Deutsche Bank | $120 | |
| Jul-28-26 | Reiterated | Guggenheim | Buy | $90 → $135 |
| Jul-16-26 | Reiterated | Mizuho | Outperform | $120 → $140 |
| Jul-13-26 | Downgrade | RBC Capital | Outperform → Sector Perform | $108 → $115 |
| Jun-29-26 | Reiterated | Truist Securities | Buy | $116 → $136 |
Latest News· Times ET
Sep-16-26
Sep-15-26
Sep-15-2608:11AM
Sep-10-26
Sep-10-2610:27AM
Sep-04-26
Sep-04-2608:37AM
Sep-03-26
Sep-03-2611:24PM
08:50AM
Sep-02-26
Sep-02-2612:01PM
Sep-01-26
Sep-01-2603:00AM
Aug-31-26
Aug-31-2612:21AM
Aug-27-26
Aug-27-2605:44AM
Aug-06-26
Aug-05-26
09:06AM
Kymera Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
Company
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 105 | 39 | 47 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | -2 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 107 | 39 | 47 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 75 | 68 | 64 | — | — | — | — | — | — | |
| Research and Development | 375 | 317 | 240 | — | — | — | — | — | — | |
| Other Operating Expense | 8 | 4 | 5 | — | — | — | — | — | — | |
| Operating Income | -351 | -349 | -262 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 50 | 38 | 38 | — | — | — | — | — | — | |
| Net Income Before Taxes | -299 | -312 | -224 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -299 | -311 | -224 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -299 | -312 | -224 | — | — | — | — | — | — | |
| Net Income | -299 | -311 | -224 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.25 | -3.69 | -2.98 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.25 | -3.69 | -2.98 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.25 | -3.69 | -2.98 | — | — | — | — | — | — | |
| EBITDA | -292 | -303 | -216 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 110.58 | 167.59 | 64.20 | — | — | — | — | — | — | |
| Gross Margin | 101.90 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -334.29 | -894.87 | -557.45 | — | — | — | — | — | — | |
| Net Margin | -284.76 | -797.44 | -476.60 | — | — | — | — | — | — | |
| Shares Outstanding | 98 | 84 | 75 | — | — | — | — | — | — | |
| Market Capitalization | 11,611 | 6,536 | 3,017 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Adams Brian | Chief Legal Officer | Sep 04 '26 | Sale | 116.83 | 6,371 | 744,297 | 50,254 | Sep 04 |
| Mainolfi Nello | Chief Executive Officer | Jul 07 '26 | Sale | 119.00 | 50,000 | 5,950,000 | 666,568 | Jul 07 |
| Mainolfi Nello | Chief Executive Officer | Jul 07 '26 | Option Exercise | 2.08 | 100,000 | 208,000 | 716,568 | Jul 07 |
| Mainolfi Nello | Chief Executive Officer | Jul 01 '26 | Sale | 115.29 | 80,000 | 9,223,528 | 666,568 | Jul 02 |
| Goodman Noah | Chief Business Officer | Jul 01 '26 | Sale | 114.29 | 3,389 | 387,329 | 47,179 | Jul 02 |
| Mainolfi Nello | Chief Executive Officer | Jul 01 '26 | Option Exercise | 2.08 | 80,000 | 166,400 | 746,568 | Jul 02 |
| Jacobs Bruce N. | Chief Financial Officer | Jun 30 '26 | Sale | 114.96 | 77,109 | 8,864,829 | 244,883 | Jul 02 |
| Jacobs Bruce N. | Chief Financial Officer | Jun 30 '26 | Option Exercise | 5.33 | 61,378 | 327,145 | 321,992 | Jul 02 |
| Booth Bruce | Director | Jun 29 '26 | Sale | 108.05 | 153,300 | 16,563,805 | 461,794 | Jul 02 |
| Booth Bruce | Director | Jun 26 '26 | Sale | 110.29 | 467,878 | 51,603,032 | 472,267 | Jun 30 |
| BVF PARTNERS L P/IL | director, other: See Remarks and Footnotes | Jun 26 '26 | Sale | 106.50 | 1,630,658 | 173,665,078 | 78,787 | Jun 26 |
| Goodman Noah | Chief Business Officer | Jun 25 '26 | Option Exercise | 21.05 | 5,000 | 105,250 | 55,195 | Jun 25 |
| Booth Bruce | Director | Jun 25 '26 | Sale | 118.76 | 548,321 | 65,119,019 | 529,718 | Jun 25 |
| Goodman Noah | Chief Business Officer | Jun 25 '26 | Sale | 114.00 | 5,000 | 570,000 | 50,195 | Jun 25 |
| Booth Bruce | Director | Jun 24 '26 | Sale | 100.51 | 134,720 | 13,540,476 | 597,047 | Jun 25 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.